Trial · NCT01348126
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
NCT01348126, Phase 2, Phase 3, Terminated, Synta Pharmaceuticals Corp.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer. Trials, record NCT01348126. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01348126
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
- NCT number
- NCT01348126
- Status
- Terminated
- Phases
- Phase 2, Phase 3
- Enrollment
- 385 participants, actual
- Lead sponsor
- Synta Pharmaceuticals Corp.
- Conditions
- Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic
- Interventions
- Docetaxel, Combination of ganetespib and docetaxel
- First posted
- 2011-05-05
- Last updated
- 2015-11-05
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival in two co-primary populations | 14 months | |
| Secondary | Overall Response Rate | 14 months | ORR is the proportion of subjects who achieve tumor response |
| Secondary | Determine qualitative and quantitative toxicities | 14 months | AEs will be graded by NCI-CTC criteria. Tabulations of adverse events by frequency, relatedness and severity will be presented. Data will be presented by treatment arm and overall. No formal statistical analyses are planned. |
| Secondary | Determine plasma drug concentrations of the combination | 14 months | Assessed via measurement of Cmax levels. |
| Secondary | Evaluate Quality of Life | 14 months | As measured by the EORTC QLQ -C30 questionnaire |
| Secondary | Disease Control Rate | 14 months | Disease Control Rate is defined as the proportion of patients with best response, according to modified RECIST 1.1, of CR, PR or SD, where the SD must be for at least 6 weeks or 12 weeks. |
| Secondary | Tumor size change | 14 months | Tumor size changes from baseline to at least 6 and 12 weeks |
| Secondary | Overall survival | 21 months |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01348126
GET https://conductscience.org/api/trials/v1/NCT01348126/registered